AI And Integrated Kidney Care Will Drive Stronger Margins And Durable Earnings Power

Catalysts

About DaVita

DaVita provides kidney care services, including dialysis and value based integrated kidney care programs, to patients in the United States and internationally.

What are the underlying business or industry changes driving this perspective?

• Ongoing technology and AI investments in clinical platforms, scheduling, call centers and revenue operations are expected to lower administrative friction, support higher collections and structurally expand operating margins and free cash flow.
• DaVita Clinical Research, with one of the largest kidney patient data sets, over 250 research sites and hundreds of trials, positions the company to help shape next generation therapies such as advanced dialyzers and new drugs, which can reinforce its leadership, support premium reimbursement and enhance long term earnings power.
• Industrywide growth in chronic kidney disease and end stage kidney disease incidence, combined with DaVita’s efforts to reduce mortality and missed treatments, is expected to translate into steady treatment volume growth and a durable revenue base over time.
• Expansion of Integrated Kidney Care and value based arrangements tied to government programs and payers can monetize DaVita’s care management capabilities, improving hospitalization rates and total cost of care, which may widen net margins as performance payments are recognized.
• Continuous optimization of payer and commercial mix, including exchange plans and Medicare Advantage, alongside systematic revenue cycle improvements, supports rising revenue per treatment and stabilizes earnings despite policy volatility.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on DaVita compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming DaVita's revenue will grow by 6.0% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 5.5% today to 6.8% in 3 years time.
• The bullish analysts expect earnings to reach $1.1 billion (and earnings per share of $22.88) by about July 2029, up from $756.4 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 15.7x on those 2029 earnings, down from 19.7x today. This future PE is lower than the current PE for the US Healthcare industry at 25.1x.
• The bullish analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.91%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Structural pressures on U.S. dialysis treatment volume, including elevated missed treatment rates, higher mortality from severe flu seasons and acute events such as hurricanes and cyber incidents, could persist beyond 2025, limiting the ability to return to sustained positive treatment growth and constraining revenue expansion over the long term.
• Shifts in payer and insurance mix driven by policy changes to enhanced premium tax credits, volatility in exchange enrollment and ongoing recalibration of the Medicare Advantage landscape may reduce the proportion of higher yielding commercial and exchange patients, pressuring revenue per treatment and compressing net margins.
• Long term increases in patient care costs from wage inflation, higher pharmaceutical usage such as greater dispensing of phosphate binders and general medical cost inflation may outpace pricing and RPT improvements, eroding the anticipated uplift in operating leverage and dampening earnings growth.
• Uncertain timing and profitability of Integrated Kidney Care and government value based programs, where revenue recognition depends on data flows and policy decisions outside DaVita’s control, could lead to volatile or lower than expected performance fees, introducing earnings variability and undermining confidence in sustainable margin expansion.
• Heavy and ongoing investments in technology infrastructure, AI, scheduling and revenue operations systems, while intended to create long term efficiencies, may deliver benefits more slowly than anticipated or face implementation hurdles, resulting in structurally higher G&A and weaker free cash flow conversion and net margins than assumed in the bullish scenario.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for DaVita is $270.0, which represents up to two standard deviations above the consensus price target of $208.57. This valuation is based on what can be assumed as the expectations of DaVita's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $270.0, and the most bearish reporting a price target of just $145.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $16.5 billion, earnings will come to $1.1 billion, and it would be trading on a PE ratio of 15.7x, assuming you use a discount rate of 7.9%.
• Given the current share price of $232.41, the analyst price target of $270.0 is 13.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.